File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Use of exogenous estrogens in systemic lupus erythematosus

TitleUse of exogenous estrogens in systemic lupus erythematosus
Authors
Issue Date2001
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/semarthrit
Citation
Seminars In Arthritis And Rheumatism, 2001, v. 30 n. 6, p. 426-435 How to Cite?
AbstractObjective: To review the current literature on the safety of using exogenous estrogens in patients with systemic lupus erythematosus (SLE). Method: A MEDLINE search for articles published between 1970 and 2000 regarding the relationship between estrogens and SLE was performed. Emphasis was put on human studies, treatment trials, and epidemiologic surveys. Results: The use of exogenous estrogens in healthy women increases the risk of SLE development. For patients with established SLE, a hypoestrogenemic state appears to be protective against severe flares, whereas exogenous estrogen administration or hyperestrogenemia induced by hormonal manipulation may exacerbate the disease in certain individuals. Both the use of oral contraceptives and the use of hormonal replacement therapy (HRT) increase the chance of venous thromboembolism. The presence of antiphospholipid antibodies may aggravate the risk of thrombosis in SLE. In retrospective studies, HRT appears to be well tolerated in postmenopausal SLE patients. Conclusions: There are no prospective data that show a deleterious effect of exogenous estrogens on disease activity in human SLE. Oral contraceptives may be considered for patients with SLE in the absence of active nephritis or antiphospholipid antibodies. The slight increase in venous thromboembolic risk should not be the chief deterrent to the use of HRT in postmenopausal SLE patients, considering its various health benefits. Copyright © 2001 by W.B. Saunders Company.
Persistent Identifierhttp://hdl.handle.net/10722/162488
ISSN
2015 Impact Factor: 3.946
2015 SCImago Journal Rankings: 1.659
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorMok, CCen_US
dc.contributor.authorLau, CSen_US
dc.contributor.authorWong, RWSen_US
dc.date.accessioned2012-09-05T05:20:28Z-
dc.date.available2012-09-05T05:20:28Z-
dc.date.issued2001en_US
dc.identifier.citationSeminars In Arthritis And Rheumatism, 2001, v. 30 n. 6, p. 426-435en_US
dc.identifier.issn0049-0172en_US
dc.identifier.urihttp://hdl.handle.net/10722/162488-
dc.description.abstractObjective: To review the current literature on the safety of using exogenous estrogens in patients with systemic lupus erythematosus (SLE). Method: A MEDLINE search for articles published between 1970 and 2000 regarding the relationship between estrogens and SLE was performed. Emphasis was put on human studies, treatment trials, and epidemiologic surveys. Results: The use of exogenous estrogens in healthy women increases the risk of SLE development. For patients with established SLE, a hypoestrogenemic state appears to be protective against severe flares, whereas exogenous estrogen administration or hyperestrogenemia induced by hormonal manipulation may exacerbate the disease in certain individuals. Both the use of oral contraceptives and the use of hormonal replacement therapy (HRT) increase the chance of venous thromboembolism. The presence of antiphospholipid antibodies may aggravate the risk of thrombosis in SLE. In retrospective studies, HRT appears to be well tolerated in postmenopausal SLE patients. Conclusions: There are no prospective data that show a deleterious effect of exogenous estrogens on disease activity in human SLE. Oral contraceptives may be considered for patients with SLE in the absence of active nephritis or antiphospholipid antibodies. The slight increase in venous thromboembolic risk should not be the chief deterrent to the use of HRT in postmenopausal SLE patients, considering its various health benefits. Copyright © 2001 by W.B. Saunders Company.en_US
dc.languageengen_US
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/semarthriten_US
dc.relation.ispartofSeminars in Arthritis and Rheumatismen_US
dc.subject.meshEstrogens - Adverse Effects - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshImmune System - Drug Effectsen_US
dc.subject.meshLupus Erythematosus, Systemic - Chemically Induced - Physiopathologyen_US
dc.subject.meshPrognosisen_US
dc.subject.meshRisk Factorsen_US
dc.subject.meshSafetyen_US
dc.subject.meshThrombosis - Chemically Induceden_US
dc.titleUse of exogenous estrogens in systemic lupus erythematosusen_US
dc.typeArticleen_US
dc.identifier.emailLau, CS:cslau@hku.hken_US
dc.identifier.authorityLau, CS=rp01348en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1053/sarh.2001.22498en_US
dc.identifier.pmid11404826-
dc.identifier.scopuseid_2-s2.0-0034966993en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034966993&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume30en_US
dc.identifier.issue6en_US
dc.identifier.spage426en_US
dc.identifier.epage435en_US
dc.identifier.isiWOS:000169277500006-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridMok, CC=34668219600en_US
dc.identifier.scopusauthoridLau, CS=14035682100en_US
dc.identifier.scopusauthoridWong, RWS=34875928200en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats